Ikena Oncology, Inc.

Ticker(s):

IKNA

Country:

Sector & Industry:

,
Business Overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Contact & Other Information

Number of Employees:

14

645 Summer Street
Suite 101
Boston

,

MA

,

2210
United States
857 273 8343

No content was found.